CD44 splice variants as potential players in Alzheimer’s disease pathology

Manuscript Number: 

16-1245R2

Author(s): 
Micha Ben Zimra, Yaron Gruper, Don Kristt, Moshe Laudon, David Naor, Elhanan Pinner, Nava Zisapel

Disclosures

Micha Ben Zimra

  • Nothing to Disclose

Yaron Gruper

  • Nothing to Disclose

Don Kristt

  • Nothing to Disclose

Moshe Laudon

  • Equity:
    I have received employee stock options from Neurim Pharmaceuticals Ltd., Israel.
    Sponsors:
    I am an employee at Neurim Pharmaceuticals Ltd., Israel.
    Patents/Royalties
    CD44 splice variants in neurodegenerative diseases Patent number: 9416166 Abstract: There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof. Type: Grant Filed: March 27, 2015 Date of Patent: August 16, 2016 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Elhanan Pinner, Moshe Laudon, Nava Zisapel CD44 SPLICE VARIANTS IN NEURODEGENERATIVE DISEASES Publication number: 20150266940 Abstract: There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof. Type: Application Filed: March 27, 2015 Publication date: September 24, 2015 Inventors: Elhanan Pinner, Moshe Laudon, Nava Zisapel Method and composition for enhancing cognition in alzheimer's patients Patent number: 9119846 Abstract: The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist. Type: Grant Filed: September 10, 2014 Date of Patent: September 1, 2015 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Methods for treating neurological disease Patent number: 9101613 Abstract: Neurological disorders and diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Down's syndrome, can be ameliorated or beneficially treated by administration of a formulation comprising an effective amount of a pyrone-indole derivative of formula (I) Ar—B—Ar???(I) wherein AR represents an indole nucleus ring system: Ar? represents an alpha-, beta- or gamma-pyrone nucleus ring system: and each of B, R1, R2, R3, R4, R1? and R2? are as defined herein. Type: Grant Filed: August 12, 2013 Date of Patent: August 11, 2015 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Moshe Laudon, Tal Peleg-Shulman CD44 splice variants in neurodegenerative diseases Patent number: 9018180 Abstract: There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof. Type: Grant Filed: July 10, 2008 Date of Patent: April 28, 2015 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Elhanan Pinner, Moshe Laudon, Nava Zisapel COMPOSITION FOR IMPROVING COGNITION AND MEMORY Publication number: 20140378512 Abstract: The invention relates to a pharmacologically active combination, having utility in treating insomnia patients, which comprises: (a) at least one first active ingredient selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists; and (b) at least one second active ingredient selected from nicotine and nicotine receptor agonists; to use of a medicament containing component (a) with or without component (b) for alleviation of at least one adverse effect which occurs in a patient in the course of nicotine replacement therapy, or otherwise, selected from impairment of the quality of sleep, impairment of cognition and impairment of memory, as well as to a kit having utility in treating insomnia patients, which comprises components (a) and (b) in unit dosage form. Type: Application Filed: September 10, 2014 Publication date: December 25, 2014 Applicant: NEURIM PHARMACEUTICALS (1991) LTD. Inventors: Nava ZISAPEL, Moshe LAUDON METHOD AND COMPOSITION FOR ENHANCING COGNITION IN ALZHEIMER'S PATIENTS Publication number: 20140377351 Abstract: The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist. Type: Application Filed: September 10, 2014 Publication date: December 25, 2014 Applicant: NEURIM PHARMACEUTICALS (1991) LTD. Inventors: Nava ZISAPEL, Moshe LAUDON Composition for improving cognition and memory Patent number: 8859593 Abstract: The invention relates to a pharmacologically active combination, having utility in treating insomnia patients, which comprises: (a) at least one first active ingredient selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists; and (b) at least one second active ingredient selected from nicotine and nicotine receptor agonists; to use of a medicament containing component (a) with or without component (b) for alleviation of at least one adverse effect which occurs in a patient in the course of nicotine replacement therapy, or otherwise, selected from impairment of the quality of sleep, impairment of cognition and impairment of memory, as well as to a kit having utility in treating insomnia patients, which comprises components (a) and (b) in unit dosage form. Type: Grant Filed: April 15, 2004 Date of Patent: October 14, 2014 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Method of treatment comprising administering controlled release melatonin Patent number: 8728511 Abstract: Controlled release melatonin formulations are useful for imparting avoidance of mood depression which may be associated with administration of melatonin in conventional form comprising. Particular embodiments of methods use formulations designed to release melatonin according to a profile that simulates a normal endogenous melatonin nocturnal profile. The methods also include co-administration with additional medicaments. Type: Grant Filed: October 25, 2011 Date of Patent: May 20, 2014 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon METHODS FOR TREATING NEUROLOGICAL DISEASE Publication number: 20130324583 Abstract: Neurological disorders and diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Down's syndrome, can be ameliorated or beneficially treated by administration of a formulation comprising an effective amount of a pyrone-indole derivative of formula (I) Ar—B—Ar???(I) wherein AR represents an indole nucleus ring system: Ar? represents an alpha-, beta- or gamma-pyrone nucleus ring system: and each of B, R1, R2, R3, R4, R1? and R2? are as defined herein. Type: Application Filed: August 12, 2013 Publication date: December 5, 2013 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Moshe Laudon, Tal Peleg-Shulman Pyrone-indole derivatives and process for their preparation Patent number: 8569355 Abstract: The present invention relates to a method for treating a variety of maladies and conditions; which comprises administering a formulation comprising an effective amount of a pyrone-indole derivative of formula (I): Ar—B—Ar???(I) wherein Ar represents an indole nucleus ring system: Ar? represents an alpha-, beta- or gamma-pyrone nucleus ring system: and each of B, R1-4, and R1-2? are one of the groups as defined herein. Type: Grant Filed: July 13, 2012 Date of Patent: October 29, 2013 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Moshe Laudon, Tal Peleg-Shulman NOVEL PYRONE-INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION Publication number: 20120302620 Abstract: The present invention relates to a method for treating a variety of maladies and conditions; which comprises administering a formulation comprising an effective amount of a pyrone-indole derivative of formula (I): Ar—B—Ar???(I) wherein Ar represents an indole nucleus ring system: Ar? represents an alpha-, beta- or gamma-pyrone nucleus ring system: and each of B, R1-4, and R1-2? are one of the groups as defined herein. Type: Application Filed: July 13, 2012 Publication date: November 29, 2012 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Moshe Laudon, Tal Peleg-Shulman 2-aminobenzoyl derivatives Patent number: 8309767 Abstract: The invention relates to 2-aminobenzoyl-alkylamines, -alkylamides and -alkylthioamides, and their application for treatment or prevention of various physiological conditions. Type: Grant Filed: June 24, 2004 Date of Patent: November 13, 2012 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon, Dvorah Daily Pyrone-indole derivatives and process for their preparation Patent number: 8242163 Abstract: The present invention relates to a method for treating insulin resistance, neuronal loss associated with stroke, ischemia, central nervous system trauma, a central nervous system disorder, a neurodegenerative disease, the adverse consequences of the over-stimulation of excitatory amino acids, a psychiatric disease, epilepsy or other convulsive disorder, chronic pain, CMV retinitis, urinary incontinence, or for inducing anesthesia; which comprises administering to an animal or human in need thereof an effective amount of a pharmaceutical formulation comprising an effective amount of a pyrone-indole derivative of formula (I): Ar—B—Ar???(I) wherein Ar represents an indole nucleus ring system: Ar? represents an alpha-, beta- or gamma-pyrone nucleus ring system: and each of B, R1-4, and R1-2? are one of the groups as defined herein. Type: Grant Filed: November 4, 2009 Date of Patent: August 14, 2012 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Moshe Laudon, Tal Peleg-Shulman Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents Patent number: 8236858 Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders. Type: Grant Filed: August 3, 2011 Date of Patent: August 7, 2012 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Tal Peleg-Shulman, Moshe Laudon, Dvorah Daily Method and Formulation for Treating Resistance to Antihypertensives and Related Conditions Publication number: 20120070501 Abstract: A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient. Type: Application Filed: October 25, 2011 Publication date: March 22, 2012 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents Publication number: 20110319494 Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders. Type: Application Filed: August 3, 2011 Publication date: December 29, 2011 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily Method and formulation for treating resistance to antihypertensives and related conditions Patent number: 8075914 Abstract: A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient. Type: Grant Filed: December 4, 2007 Date of Patent: December 13, 2011 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents Patent number: 8003702 Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders. Type: Grant Filed: November 3, 2009 Date of Patent: August 23, 2011 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily CD44 SPLICE VARIANTS IN NEURODEGENERATIVE DISEASES Publication number: 20110172286 Abstract: There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof. Type: Application Filed: July 10, 2008 Publication date: July 14, 2011 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Elhanan Pinner, Moshe Laudon, Nava Zisapel Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents Publication number: 20100048663 Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders. Type: Application Filed: November 3, 2009 Publication date: February 25, 2010 Applicant: NEURIM PHARMACEUTICALS (1991) LTD. Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily Novel Pyrone-Indole Derivatives and Process for Their Preparation Publication number: 20100048662 Abstract: The present invention relates to novel pyrone-indole derivatives, pharmaceutical formulations containing them, and use of the compounds in the manufacture of Medicaments for treating or preventing various diseases. Type: Application Filed: November 4, 2009 Publication date: February 25, 2010 Applicant: NEURIM PHARMACEUTICALS (1991) LTD. Inventors: Moshe Laudon, Tal Peleg-Shulman Pyrone-indole derivatives and process for their preparation Patent number: 7635710 Abstract: The present invention relates to novel pyrone-indole derivatives, pharmaceutical formulations containing them, and use of the compounds in the manufacture of Medicaments for treating or preventing various diseases. Type: Grant Filed: February 12, 2007 Date of Patent: December 22, 2009 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Moshe Laudon, Tal Peleg-Shulman Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents Patent number: 7622495 Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders. Type: Grant Filed: October 1, 2007 Date of Patent: November 24, 2009 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents Publication number: 20080132559 Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders. Type: Application Filed: October 1, 2007 Publication date: June 5, 2008 Applicant: NEURIM PHARMACEUTICALS (1991) LTD. Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily Method and Formulation for Treating Resistance to Antihypertensives and Related Conditions Publication number: 20080085317 Abstract: A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient. Type: Application Filed: December 4, 2007 Publication date: April 10, 2008 Applicant: NEURIM PHARMACEUTICALS (1991) LTD. Inventors: Nava Zisapel, Moshe Laudon Indole derivatives Patent number: 7355054 Abstract: The invention relates to 1-(R1)-2-(R2)-3-(Y—X—NH-A- or Z-A-)-4,5,6,7-R)0-4-indoles, and their acid addition salts where the compounds are basic, wherein A is C1-4 alkylene, X is >CH2, >C?O or >C?S, and the other symbols have various defined values, and to pharmaceutical, skin-protective and cosmetic compositions which comprise them. Type: Grant Filed: January 11, 2005 Date of Patent: April 8, 2008 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Method and formulation for treating resistance to antihypertensives and related conditions Patent number: 7332177 Abstract: A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient. Type: Grant Filed: January 5, 2000 Date of Patent: February 19, 2008 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Novel pyrone-indole derivatives and process for their preparation Publication number: 20080027121 Abstract: The present invention relates to novel pyrone-indole derivatives, pharmaceutical formulations containing them, and use of the compounds in the manufacture of Medicaments for treating or preventing various diseases. Type: Application Filed: February 12, 2007 Publication date: January 31, 2008 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Moshe Laudon, Tal Peleg-Shulman 2-Aminobenzoyl derivatives Publication number: 20060270733 Abstract: The invention relates to 2-aminobenzoyl-alkylamines, -alkylamides and -alkylthioamides, and their application for treatment or prevention of various physiological conditions. Type: Application Filed: June 24, 2004 Publication date: November 30, 2006 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon, Dvorah Daily Composition for improving cognition and memory Publication number: 20060229340 Abstract: The invention relates to a pharmacologically active combination, having utility in treating insomnia patients, which comprises: (a) at least one first active ingredient selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists; and (b) at least one second active ingredient selected from nicotine and nicotine receptor agonists; to use of a medicament containing component (a) with or without component (b) for alleviation of at least one adverse effect which occurs in a patient in the course of nicotine replacement therapy, or otherwise, selected from impairment of the quality of sleep, impairment of cognition and impairment of memory, as well as to a kit having utility in treating insomnia patients, which comprises components (a) and (b) in unit dosage form. Type: Application Filed: April 15, 2004 Publication date: October 12, 2006 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Indole derivatives Publication number: 20050159463 Abstract: The invention relates to 1-(R1)-2-(R2)-3-(Y-X-NH-A- or Z-A-)-4,5,6,7-R)0-4-indoles, and their acid addition salts where the compounds are basic, wherein A is C1-4 alkylene, X is >CH2, >C=O or >C=S, and the other symbols have various defined values, and to pharmaceutical, skin-protective and cosmetic compositions which comprise them. Type: Application Filed: January 11, 2005 Publication date: July 21, 2005 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Indole derivatives Patent number: 6858642 Abstract: The invention relates to 1-(R1)-2-(R2)-3-(Y-X—NH-A- or Z-A-)-4,5,6,7-R)0.4-indoles, and their acid addition salts where the compounds are basic, wherein A is C1-4 alkylene, X is >CH2, >C?O or >C?S, and the other symbols have various defined values, and to pharmaceutical, skin-protective and cosmetic compositions which comprise them. Type: Grant Filed: May 24, 2000 Date of Patent: February 22, 2005 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them Publication number: 20050020664 Abstract: This invention relates to the administration of novel substituted tryptamines and related derivatives for the treatment of several types of medical conditions, such as prostate conditions, impotence, cardiovascula disorders, central nervous system and psychiatric disorders (such as sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (such as jet lag, delayed sleep syndrome, shift-work-associated sleep disorder or seasonal affective disorder), endocrine indications, neoplastic conditions, conditions associated with senescence, ophthalmological diseases, cluster headaches and migraines, and weight gain disorders. Type: Application Filed: August 20, 2004 Publication date: January 27, 2005 Applicant: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Derivating of tryptamine and analogous compounds and pharmaceutical formulations containing them Patent number: 6780884 Abstract: This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous system and psychiatric disorders (sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder), neoplastic conditions, and conditions associated with senescence. Type: Grant Filed: August 28, 2003 Date of Patent: August 24, 2004 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Derivating of tryptamine and analogous componds and pharmaceutical formulations containing them Publication number: 20040029950 Abstract: This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous system and psychiatric disorders (sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder), neoplastic conditions, and conditions associated with senescence. Type: Application Filed: August 28, 2003 Publication date: February 12, 2004 Inventors: Nava Zisapel, Moshe Laudon Therapeutic uses of melatonin Patent number: 6566389 Abstract: A method for treating or preventing symptoms of tardive dyskensia comprises administering melatonin to patient exhibiting or liable to develop such symptoms. The melatonin is administered in an amount effective to ameliorate or prevent symptoms of tardive dyskensia developing in the patient. Type: Grant Filed: November 26, 2001 Date of Patent: May 20, 2003 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Nava Zisapel, Moshe Laudon Method for determination of urine components and for preventing sudden infant death syndrome Patent number: 5500225 Abstract: Non-volatile organic components of interest in the urine of humans using diapers are assayed by carrying out the following sequence of steps at least once and up to as many times as the diapers are changed in a given 24-hour period, namely: removing the outer cover and any extraneous material from a used diaper so as to leave only diaper pulp with absorbed urine, estimating the amount of water in the used diaper, extracting a weighed portion of the diaper pulp with a water-miscible organic solvent, in which the diaper pulp is insoluble, to give an extract containing a component of interest, and determining the amount of the component of interest per unit volume of urine absorbed on the diaper pulp by analyzing an aliquot of the extract. The method may be applied e.g. to the prevention of sudden infant death syndrome in infants, by selecting infants for medication with melatonin where diaper urine indicates a deficiency of its metabolite 6-sulfatoxymelatonin in a 24-hour period. Type: Grant Filed: October 19, 1993 Date of Patent: March 19, 1996 Assignee: Neurim Pharmaceuticals (1991) Ltd. Inventors: Moshe Laudon, Nava Zisapel Melatonin antagonist Patent number: 4880826 Abstract: The invention relates to novel derivatives of melatonin, to the production of such new derivatives, to labelled forms, and especially radioactively tagged forms of such compounds, to assays for melatonin receptor function based on such radioactively tagged compounds and to pharmaceutical compositions which contain such novel non-labelled compounds.The novel compounds are potent antagonists of melatonin which are of value in human medicine and also in animal husbandry. Type: Grant Filed: June 25, 1987 Date of Patent: November 14, 1989 Inventors: Nava Zisapel, Moshe Laudon

David Naor

  • Nothing to Disclose

Elhanan Pinner

  • Sponsors:
    Monthly salary

Nava Zisapel

  • Equity:
    I am the founder and Chief Science Officer of Neurim Pharmaceuticals
    Sponsors:
    I am the founder and Chief Science Officer of Neurim Pharmaceuticals